Recombinant Human GPA33 / A33 Protein, His-Tag, 50 µg

Background
Glycoprotein A33 (GPA33) is also known as Cell surface A33 antigen, is a single-pass type I membrane protein which is expressed in normal gastrointestinal epithelium and in 95% of colon cancers. GPA33 The predicted mature protein has a 213-amino acid extracellular region, a single transmembrane domain, and a 62-amino acid intracellular tail. The sequence of the extracellular region contains 1 Ig-like C2-type (immunoglobulin-like) domain and 1 Ig-like V-type (immunoglobulin-like) domain characteristic of the CD2 subgroup of the immunoglobulin (Ig) superfamily, which contains. GPA33 may play a role in cell-cell recognition and signaling.

Source
Human GPA33 / A33 Protein (Human GPA33, His Tag(GP3-H5224) is expressed from human 293 cells (HEK293). It contains AA Ile 22 - Val 235 (Accession # AAH74830).
Predicted N-terminus: Ile 22

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 24.4 kDa. The protein migrates as 33-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>96% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Defining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function"
Gootjes, Zwaginga, Roep et al
Cells (2024) 13 (11)
(2) "Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation"
O'Neill, Yébenes Mayordomo, Mitulović et al
Mol Cell Proteomics (2024) 23 (6), 100764
(3) "Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment"
Narbona, Hernández-Baraza, Gordo et al
Biomolecules (2023) 13 (7)
Showing 1-3 of 111 papers.